{
  "kind": "treatment",
  "slug": "amineptine-survector",
  "type": "antidepressant",
  "name": "Amineptine (Survector)",
  "summary": "A tricyclic antidepressant with dopaminergic reuptake inhibition, formerly used for depression but withdrawn in most markets.",
  "description": "Amineptine is an atypical tricyclic antidepressant that primarily inhibits dopamine reuptake with mild norepinephrine reuptake inhibition. It was used for the treatment of major depressive disorder, particularly with psychomotor retardation. Due to concerns about hepatotoxicity and potential for abuse, it has been withdrawn from the market in most countries.",
  "category": "medications/antidepressants",
  "tags": [
    "tricyclic",
    "dopamine-reuptake-inhibitor",
    "withdrawn",
    "depression"
  ],
  "metadata": {
    "drug_classes": [
      "Tricyclic Antidepressant",
      "Dopamine Reuptake Inhibitor"
    ],
    "therapeutic_categories": [
      "Depression",
      "Mood Disorders"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Withdrawn in most markets",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Survector"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term (historical)"
    ],
    "specialty_areas": [
      "Psychiatry"
    ],
    "fda_approval_year": 1978
  },
  "clinical_metadata": {
    "primary_indications": [
      "Depression"
    ],
    "off_label_uses": [],
    "contraindications": [
      "Liver disease",
      "History of drug abuse",
      "Known hypersensitivity to amineptine"
    ],
    "monitoring_required": [
      "Liver function tests during use"
    ],
    "efficacy_rating": {
      "depression": 3,
      "overall_tolerability": 2
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "amineptine",
      "survector",
      "dopamine reuptake inhibitor",
      "TCA"
    ],
    "synonyms": [],
    "common_misspellings": [
      "aminaptine",
      "ameneptine"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Major Depressive Disorder (historical use)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Inhibits dopamine reuptake, leading to increased dopaminergic activity, with weaker effects on norepinephrine reuptake; minimal serotonergic activity."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "100 mg once daily",
        "titrate": "Increase to 200 mg/day in divided doses if needed",
        "max": "200 mg/day"
      },
      "geriatric": "Use with caution; limited data",
      "hepatic_impairment": "Contraindicated",
      "renal_impairment": "Use with caution"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 100 mg (historical)"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset of mood improvement often within the first week; full effects in 2â€“4 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "insomnia",
        "nervousness",
        "dry mouth",
        "constipation"
      ],
      "less_common": [
        "palpitations",
        "skin rashes"
      ],
      "serious": [
        "hepatotoxicity",
        "abuse potential leading to dependence"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Withdrawn in many countries due to hepatotoxicity and abuse potential"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Hypertensive crisis",
          "action": "Avoid; 14-day washout"
        },
        {
          "with": "Alcohol",
          "risk": "Increased CNS effects",
          "action": "Avoid"
        },
        {
          "with": "Other hepatotoxic drugs",
          "risk": "Additive liver injury",
          "action": "Avoid"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Liver function tests regularly",
        "Signs of misuse or abuse"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Avoid unless benefits outweigh risks; data limited.",
      "lactation": "Unknown excretion; avoid if possible.",
      "pediatrics": "Not established.",
      "geriatrics": "Use caution; start at lower dose if used."
    },
    {
      "type": "tapering",
      "text": "Gradual tapering recommended to avoid withdrawal-like symptoms."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Once popular in Europe for depression with fatigue and psychomotor slowing.",
        "Liver toxicity can occur after short durations of use.",
        "Abuse reported due to dopaminergic stimulant-like effects."
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "WHO Drug Information",
          "url": "https://www.who.int/publications/"
        },
        {
          "label": "European Medicines Agency Withdrawal Notice",
          "url": "https://www.ema.europa.eu/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Amineptine (Survector): Historical Antidepressant Profile",
    "description": "Overview of amineptine, a withdrawn tricyclic antidepressant with dopaminergic action, including historical use, risks, and safety concerns."
  }
}
